Multiple clinical trials, reviews, and meta-analyses demonstrate that certain antidepressants and reuptake inhibitors (such as SNRIs, NDRIs, and multi-reuptake inhibitors like atomoxetine, viloxazine, and centanafadine) effectively treat ADHD symptoms across both pediatric and adult populations.
Evidence for · 8
Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: Implications for treatment of attention‐deficit hyperactivity disorder
2012 · cited by 59
EB-1020, a dual norepinephrine and dopamine reuptake inhibitor, successfully decreased immobility in an animal model of depression and reduced hyperactivity in an animal model of ADHD.
See more details
More for · 7
Use of Serotonin Norepinephrine Reuptake Inhibitors in the Treatment of Attention-Deficit Hyperactivity Disorder in Pediatrics
2013 · cited by 20
Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, showed patient improvement in pediatric ADHD trials.
What value do norepinephrine/dopamine dual reuptake inhibitors have to the current treatment of adult attention deficit hyperactivity disorder (ADHD) treatment armamentarium?
2022 · cited by 8
Norepinephrine and dopamine reuptake inhibitors act as key nonstimulant medications used to effectively treat ADHD symptoms.
Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial.
2025 · cited by 7
Centanafadine, a norepinephrine, dopamine, and serotonin reuptake inhibitor, demonstrated significant efficacy in reducing ADHD symptoms in adolescents.
The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium
2024 · cited by 5
Adrenergic neurotransmitter reuptake inhibitors provide effective treatment options for ADHD, particularly when patients have comorbid conditions such as depression.
Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder.
2022 · cited by 3
A meta-analysis confirmed the efficacy of norepinephrine reuptake inhibitors like atomoxetine in treating ADHD.
52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder
2025 · cited by 3
Centanafadine sustained release demonstrated long-term safety and effectiveness in treating adults with ADHD.
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial.
2026 · cited by 0
Viloxazine extended release, a non-stimulant modulating medication, significantly improved ADHD, depression, and anxiety symptoms in adults.